Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T1675
- Development stage
- Discontinued
- Lead developer
- Théa Pharmaceuticals
- Administration
- Oral
01
Overview
T1675 is an orally administered dietary formulation of omega-3 and omega-6 polyunsaturated essential fatty acids developed by Théa for moderate dry eye syndrome in patients already using tear substitutes. It was evaluated against placebo during six months of supplementation in a registered clinical study; the publicly available trial description does not identify the individual fatty acids, their doses, or a specific molecular target. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00357201))
- Brand names
- Nutrilarm
- Other names
- T1675 dietary formulationT-1675 dietary formulationT 1675 dietary formulationT1675 food supplementT-1675 food supplementT 1675 food supplement
Beyond the preview
Go deeper on T1675.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T1675.